ajooni biotech ltd Directors report


To

The Members Ajooni Biotech Limited

Your Directors present the 13th Annual Report on the business and operations of the Company along with the Audited Financial Statements for the Financial Year ("FY") ended 31st March, 2023.

1. FINANCIAL RESULTS

The highlights of the financial statement of your Company for the year under review along with previous years figures are given as under:

Particulars 31/03/2023 31/03/2022
Revenue from Operations 74,48,76,998 74,03,77,673
Other Income 29,41,428 3,81,292
Profit/loss before Depreciation, Finance Costs, Exceptional items and Tax Expense 3,06,00,129 3,11,18,901
Less: Depreciation/Amortization/Impairment 1,00,49,045 1,11,07,074
Profit /loss before Finance Costs, Exceptional items and Tax Expense 2,05,51,084 2,00,11,827
Less: Finance Costs 47,82,678 54,00,692
Profit /loss before Exceptional items and Tax Expense 1,57,68,406 1,46,11,135
Add/(less): Exceptional items - -
Profit /loss before Tax Expense 1,57,68,406 1,46,11,135
Less: Tax Expense Current Tax 54,23,760 44,76,260
Deferred Tax 9,01,993 3,53,354
MAT Credit Entitlement -
Profit /loss for the year 1,12,46,639 1,04,88,229

2. REVIEW OF OPERATION

In the financial year 2022-2023 revenue from operations of your Company was Rs 74,48,76,998/- as compared to the last year of Rs. 74,03,77,673/-. During the financial year 2022-23 the Company earned a profit of Rs. 1,12,46,639/- against the profit of Rs. 1,04,88,229/- during the previous year 202122. Your Directors expect to achieve better performance in the future taking maximum efforts to control the costs and optimize the results in the coming years.

3. TRANSFER TO RESERVES

The company has transferred Rs. 1,12,46,639 /- being the profit for the current financial year to Reserves & Surplus Account.

4. CHANGE IN NATURE OF BUSINESS

There is no change in the nature of the business of the company.

5. MATERIAL CHANGES AFFECTING THE FINANCIAL POSITION OF THE COMPANY

During the year under review, no material change took place which may affect the financial position of the Company.

6. DIVIDEND

The Company has earned a profit of Rs. 1,12,46,639/- during the period under review, but with a view of augmenting financial resources for generating stable growth in future, the Board of Directors of the company have decided to carry forward entire profit and hence do not propose to recommend any dividend for the financial year on equity shares.

7. DEPOSITS

During the year under review, the Company has not accepted any Fixed Deposits from its Members in accordance with the provisions of Sections 73, 76 and other applicable provisions of the Companies Act, 2013 ("the Act") and the Companies (Acceptance of Deposits) Rules, 2014.

8. CHANGES IN SHARE CAPITAL, IF ANY

a) Authorised Capital

During the year under review, Companys authorised share capital remained same i.e. Rs. 25 crores (Rupees Twenty Five Crore only) divided into 2,50,00,000 (Two Crore Fifty Lakhs only) equity shares of Rs. 10/- (Rupees Ten only) but due to subdivision of equity shares of nominal face value of Rs. 10/- to nominal face value of Rs. 2/- each, the authorized capital was amended into 12,50,00,000 equity shares of Rs. 2 each. Hence, there was no change in the amount of authorized capital, consequent upon sub division of equity shares.

b) Issued, Subscribed & Paid up Capital

During the year under review, due to sub-division of equity shares of nominal face value of Rs. 10/- to nominal face value of Rs. 2/- each, Companys

Issued, Subscribed & Paid up Capital was amended into 5,00,27,910 equity shares of Rs. 2 each.

Further, the paid-up share capital of the Company was increased from Rs. 10,00,55,820/- to Rs. 17,52,27,443/- pursuant to allotment of 3,75,85,811 equity shares of Rs. 6 each (including premium of Rs. 4 each) fully paid-up under Rights issue.

Therefore, Companys paid up share capital has increased from Rs. 10,00,55,820/- (Rupees Ten Crore Fifty-Five Thousand Eight Hundred and Twenty only) divided into 5,00,27,910 equity shares of Rs. 2 each/- to Rs. 17,52,27,442/- (Rupees Seventeen Crore Fifty- Two Lakhs Twenty-Seven Thousand Four Hundred and Forty-Two only) divided into 8,76,13,721 (equity shares of Rs. 2 each.

9. FINANCIAL STATEMENTS

The Financial statements have been prepared by the Companys Management in accordance with the requirements of Accounting Standards 21 issued by Institute of Chartered Accountants of India (ICAI) and as per the provisions of Companies Act, 2013.

10. EXTRACT OF ANNUAL RETURN

Pursuant to the provisions of Section 134(3)(a) and 92(3) of the Act read with Rule 12(1) of the Companies (Management and Administration) Rules, 2014, as amended, the Annual Return of the Company will be available on the website of the Company and can be accessed through the following link

https://www.aioonibiotech.com/annualreport.php.

11. NUMBER OF BOARD MEETINGS

The Board has met 10 (Ten) times during the financial year, the details of which are as under:

09.05.2022, 05.08.2022, 25.08.2022, 26.09.2022,

17.10.2022, 04.11.2022, 11.11.2022, 24.12.2022, 14.02.2022 and 27.03.2023. The maximum interval between any two meetings didnt exceed 120 days, as prescribed in the Companies Act, 2013.

The details of meetings of the Board and attendance of the directors are provided in the Report on Corporate Governance which forms the part of this report.

12. COMPOSITION OF COMMITTEES

As per the applicable provisions of the Companies Act, 2013 & Securities Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015, three Committees have been constituted in the company which are as follows: -

a) Audit Committee

b) Nomination & Remuneration Committee

c) Stakeholder Relationship Committee

The details of meetings of the committees and attendance of the members are provided in the Report on Corporate Governance which forms the part of this report.

13. CHANGE IN DIRECTORS /KEY MANAGERIAL PERSONNEL DURING THE YEAR

The details about the changes in Directors or Key Managerial Personnel by way of Appointment, redesignation, Resignation, Death, dis-qualification, variation made or withdrawn etc. are as follows:

S.NO. NAME DESIGNAT

ION

NATURE

OF

CHANGE

WITH

EFFECT

FROM

1 GURSIM

RAN

SINGH

WHOLE

TIME

DIRECTOR

RE-

DESIGNAT

ION

20/09/

2022

In accordance with the provisions of Section 152(6) of the Companies Act, 2013 and the Companys Articles of Association, Mr. Gursimran Singh (DIN: 02209675) Whole Time Director of the Company is liable to retire by rotation at the ensuing AGM, and being eligible, has offered himself for reappointment.

14. RE-APPOINTMENT OF INDEPENDENT DIRECTOR

Upon recommendation of the Nomination and Remuneration Committee and the Board of Directors at their Meetings held on August 25, 2022, approval was granted by the Shareholders of the Company dated September 20, 2022, for:

1. Re-appointment of Mrs. Simmi Chhabra (DIN: 07870398) as the Independent Director (NonExecutive Director) of the Company for his second term from 5 years starting from August 25, 2022.

2. Re-appointment of Mr. Ramandeep Singh (DIN: 07896086) as the Independent Director (NonExecutive Director) of the Company for his second term from 5 years starting from August 25, 2022.

3. Re-appointment of Mr. Imteshwar Singh Bhatia

(DIN: 07864007) as the Independent Director

(Non-Executive Director) of the Company for his second term starting from 5 years starting from August 25, 2022.

15. STATEMENT ON DECLARATION GIVEN BY INDEPENDENT DIRECTORS UNDER SECTION 149(6) OF COMPANIES ACT, 2013

All Independent Directors have given declarations under section 149(7) that they meet the criteria of Independence as laid down under section 149(6) of the Companies Act, 2013 and Rules made thereunder to be read with Regulation 25 of the SEBI (Listing Obligation & Disclosure Requirement) Regulation, 2015.

The meeting of the Independent Directors was held on 01st March 2023, as per schedule IV of the Companies Act, 2013. All the directors attended the meeting.

None of the Directors of your Company is disqualified under Section 162 (2) of the Companies Act, 2013. As required by law, this position is also reflected in the Auditors Report.

16. REMUNERATION

The details of the remuneration given to the Board of Directors and Key Managerial Personnel have been given in the extract of Annual Return -MGT-9 and copy of the Annual Return is placed on the website of your Company at https://www.aioonibiotech.com/annualreport.php.

17. PARTICULARS OF CONTRACTS OR ARRANGEMENTS MADE WITH RELATED PARTIES

In accordance with the requirements of the Companies Act and Listing Regulations, your Company has also adopted the Policy on Related Party Transactions and same is available on website of the Company at https://www.aioonibiotech.com/pdf/RELATED%20P ARTY%20TRANSACTION%20POLICY.pdf.

All RPT entered into during the financial year 202223 were in the ordinary course of business and were on at arms length basis and were placed before the Audit Committee for its approval. In the financial year 2022-23, Details of Related Party as defined under Section 188 of the Act and Regulations 23 the Listing Regulations and their contracts or arrangements with Company are given in Notes to Account of Financial Statements. Form AOC-2 is attached as an "Annexure-A".

18. PARTICULARS OF EMPLOYEES

Information as required under Section 197(12) of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, and subsequent amendments thereto, is annexed to this Boards Report and marked as Annexure "B".

19. CORPORATE SOCIAL RESPONSIBILITY (CSR)

The provisions of Section 135 of the Companies Act relating to Corporate Social Responsibility are not applicable as the Company is having Net worth less than rupees Five Hundred Crore, Turnover less than rupees One Thousand Crore and Net Profit less than rupees Five Crore.

20. MANNER OF BOARD EVALUATION

Pursuant to the provisions of the Companies Act, 2013 and regulation 17(10) of SEBI (LODR) Regulation 2015, a structured procedure was adopted after taking into consideration of the various aspects of the Boards functioning composition of the Board and its committees, execution and performance of specific duties, obligations and governance.

The performance evaluation of the independent Directors was completed in time. The performance evaluation of the Chairman and the Nonindependent Directors was carried out by the Independent Directors. The Board of Directors expresses their satisfaction with the evaluation process.

The performance of each committee has been evaluated by its members and found to be highly satisfactory. On the basis of this exercise, the Board has decided that all Independent Directors should continue to be on the Board.

21. CORPORATE GOVERNANCE REPORT

As per Reg. 34 of SEBI Regulation, 2015 to be read with Part A of Schedule V of the said regulations, a separate section on corporate governance practices followed by the company, together with the certificate from the Statutory Auditor of the company, confirming compliance forms an integral part of this Report.

22. MANAGEMENT DISCUSSION ANALYSIS REPORT

Management Discussion and Analysis Report for the year under review, as stipulated under Regulation 34 and Schedule V of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, is presented in a separate section of this Annual Report as "Annexure-C".

23. SUBSIDIARIES/ ASSOCIATES/JOINT VENTURES

The Company has no subsidiary/Joint ventures/Associate Companies as per the provisions of Companies Act, 2013 during the financial year ended on 31st March, 2023.

24. ADOPTION OF INDIAN ACCOUNTING STANDARD (INDAS)

Keeping in view of the above applicability, the Company has followed the Indian Accounting Standards notified under Section 133 of Companies Act, 2013 read with Companies (Indian Accounting Standards (Ind AS) Rules, 2015 for preparation of its financial statements for the year ended 31st March 2023.

25. DIRECTOR S RESPONSIBILITY STATEMENT

Pursuant to the requirement under Section 134 (5) of the Companies Act, 2013, with respect to Directors Responsibilities Statement, it is hereby confirmed:

a) That in the preparation of the annual accounts for the financial year ended 31st March, 2023 the applicable Accounting standards had been followed along with proper explanation relating to material departures;

b) That the Directors have selected such accounting policies and applied them consistently and made judgments and estimates that were reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit or loss of the Company for the year review;

c) That the Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

d) The Directors had prepared the accounts for the financial year ended 31st March, 2023 on a going concern basis; and

e) The Directors had laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively;

f) The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

26. DETAILS OF CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS AND OUTGO

The Provisions of Section 134(3) (m) of the Companies Act, 2013 read with Rule 8 of Companies (Accounts) Rules, 2014 regarding Conservation of Energy and Technology Absorption do not apply to your company for the period under review. Further, there were no foreign exchange earnings or outgo during the year under review. However, the management has taken all the necessary steps to conserve the resources to the extent possible. "Annexure - D".

27. SECRETARIAL AUDITOR AND SECRETARIAL AUDIT REPORT

As required under section 204 (1) of the Companies Act, 2013 and Rules made there under the Company has appointed M/s. MR CHECHI & Associates, Company Secretaries, Chandigarh as Secretarial

Auditor to conduct the Secretarial Audit of the Company for the financial Year 2022-23. The Secretarial Audit Report which is given in Form No. MR-3 for the financial year ended 31st March 2023 is attached as "Annexure E" to this Report

Observations Remarks/Reply
1. During the financial year under review, the disclosure of related party transactions for the half year ended 31st March, 2022 was required to be made within 15 days from the date of publication of financial results i.e. 09th May, 2022 pursuant to Regulation 23 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. However, the said disclosure was made by the company on 27th May, 2022 i.e. after a delay of 3 days. Resultantly, the stock exchange has imposed a fine of Rs. 17,700/- on the company and its directors. The company has always been meticulous in compliance with the SEBI Regulations/ Companies Act, 2013. The disclosure of related party transactions for the half year ended 31st March, 2022 was filed with a delay of 3 days. This was due to non-availability of XBRL Utility on NEAPS and NSE Digital Platform till the due date of filing said disclosure. Further the company continuously kept on tracking the new XBRL format on the NEAPS portal and NSE Digital Platform for submission of disclosures till 26th May, 2022. Accordingly as advised by the stock exchange on 27th May, 2022 the disclosure of the related party transactions was filed in pdf format on the same day i.e. 27th May, 2022. Further the fine imposed on the company has been paid.

However, the company has noted the Regulation 23 of SEBI (Prohibition of Insider Trading) Regulations, 2015.

2. During the financial year under review, the company did not submit the details of Chairperson of the committees of the Board under the head "detail of composition of committees" in the Corporate Governance Report submitted for the quarter ended 30th September, 2022. Therefore, the stock exchange had imposed a fine of Rs. 6,51,360 on the company and its directors for the violation of provisions of Regulation 27, 18(1), 19(2) and 20(2) of (SEBI (LODR) Regulations, 2015. It is hereby clarified that inadvertently the option "Member" was selected under the head "Chairperson/Membership" in thedetail of composition of committees formed by the company in the Corporate Governance Report submitted by the company for the quarter ended 30th September, 2022. Further there was no change in the composition of the committees during the financial year under review. Hence, after the continuous follow up by the company the orders for reversal of fine was issued by the stock exchange.
3. During the financial year under review, the company had not submitted the statement of cash flows along with unaudited financial results for the quarter and half year ended 30th September, 2022 in pdf format as required under Regulation 27 of (SEBI (LODR) Regulations, 2015 which were submitted on 11th November, 2022. Resultantly, the stock exchange had imposed a fine of Rs. 1,71,100 on the company and its directors. The company had submitted the financial results for the Quarter and Half Year ended 30th September. 2022 within the prescribed time i.e. on 11th November 2022 in both pdf and XBRL format. However, due to an inadvertent mistake the Cash Flow Statement could not be attached with the pdf file which was uploaded on the website of the stock exchange. This came to the notice of the company on receipt of an email from stock exchange on 12th December, 2022 and the management immediately submitted the Cash Flow Statement in pdf format with the stock exchange. Further the company has applied the application for waiver of fine with the stock exchange and the same is accepted/ approved by the stock exchange.

28. ANNUAL SECRETARIAL COMPLIANCE REPORT

The provisions of Regulation 24A of the SEBI (LODR) Regulations, 2015 are applicable on the company for the financial Year 2022-23. The company has obtained the compliance report from M/s. MR CHECHI & Associates, Company Secretaries,

Chandigarh. The Secretarial Compliance Report for the financial year ended 31st March 2023 is attached as "Annexure F" to this Report. Following is the observation to the report.

Observations Remarks/ Reply
1. The disclosure of related party transactions for the half year ended 31st March, 2022 was required to be made within 15 days from the date of publication of financial results i.e. 09th May, 2022. However, the disclosure of related party transactions was made on 27th May, 2022. The company has always been meticulous in compliance with the SEBI Regulations/ Companies Act, 2013. The disclosure of related party transactions for the half year ended 31st March, 2022 was filed with a delay of 3 days. This is due to non availability of XBRL Utility on NEAPS and NSE Digital Platform till the due date of filing said disclosure. Further the company continuously kept on tracking the new XBRL format on the NEAPS portal and NSE Digital Platform for submission of disclosures till 26th May, 2022. Accordingly as advised by the stock exchange on 27th May, 2022 the disclosure of the related party transactions was filed in pdf format on the same day i.e. 27th May, 2022. Further the fine imposed on the company has been paid.
However, the company has noted the Regulation 23 of SEBI (Prohibition of Insider Trading) Regulations, 2015.
2. The details of the Chairperson of the committees of the Board could not be submitted under the head "detail of composition of committees" in the Corporate Governance Report submitted for the quarter ended 30th September, 2022. It is hereby clarified that inadvertently the option "Member" was selected under the head "Chairperson/Membership" in the detail of composition of committees formed by the company in the Corporate Governance Report submitted by the company for the quarter ended 30th September, 2022. Further there was no change in the composition of the committees during the financial year under review. Hence, after the continuous follow up by the company the orders for reversal of fine was issued by the stock exchange.
3. The company had not submitted the statement of cash flows along with unaudited financial results for the quarter and half year ended 30th September, 2022 which were submitted on 11th November, 2022. The company had submitted the financial results for the Quarter and Half Year ended 30th September. 2022 within the prescribed time i.e. on 11th November 2022 in both pdf and XBRL format. However, due to an inadvertent mistake the Cash Flow Statement could not be attached with the pdf file which was uploaded on the website of the stock exchange. This came to the notice of the company on receipt of an email from stock exchange on 12th December, 2022 and the management immediately submitted the Cash Flow Statement in pdf format with the stock exchange. Further the company has applied the application for waiver of fine with the stock exchange and the same is accepted/ approved by the stock exchange.

29. STATUTORY AUDITORS & AUDITORS REPORT

M/s Harjeet Parvesh & Company (FRN NO. 017437N), Chartered Accountants (Peer Review Certificate No. 011668) were re-appointed as Statutory Auditors of the Company at the Annual General Meeting held on 30th September 2019, for the second term of five consecutive years i.e. for a period of five years commencing from the conclusion of 09th Annual General Meeting till the conclusion of the 14th Annual General Meeting of the Company to be held in the year 2024 and shall continue to be statutory auditors of the company for the Financial Year 2023-2024. The Auditors have confirmed that they are not disqualified from being re-appointed as Auditors of the Company. The Report given by the Auditors on the financial statement of the Company is part of this Report as Annexure "G".

There has been no qualification, reservation, adverse remark or disclaimer given by the Auditors in their Report. During the year under review, the Auditors had not reported any matter under Section 143 (12) of the Companies Act, 2013.

30. REPORTING OF FRAUDS BY AUDITORS

During the year under review, the Statutory Auditors and Secretarial Auditor have not reported any instances of frauds committed by the Company, by its officer or employees to the Audit Committee under Section 143(12) of the Act, including rules made there under (if any) details of which needs to be mentioned in this Report.

31. CASH FLOW ANALYSIS

In conformity with the provisions of Clause 34(2) of SEBI (LODR) Regulations, 2015, the Cash Flow Statement for the year ended on 31st March, 2023 forms an integral part of the Financial Statements.

32. RISK MANAGEMENT POLICY

The Provisions of Section 134(3) (n) of the Companies Act, 2013 read with provisions of Regulation 21 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 regarding implementation of a risk management policy and constitution of Risk Management committee do not apply to your company for the period under review.

However, Your Company follows a comprehensive system of Risk Management. It ensures that all the risks are timely defined and mitigated including identification of elements of risk which might threaten the existence of the Company.

33. NOMINATION & REMUNERATION COMMITTEE POLICY

Your Board has framed a policy which lays down a framework in relation to remuneration of Directors, Key Managerial Personnel and Senior Management Personnel of the Company. This policy also lays down criteria for selection and appointment of Board Members. The detail of this policy is explained in the Report on Corporate Governance. The Nomination and remuneration Policy is available on the website of the company at www.ajoonibiotech.com and direct web link to the policy is at

https://www.ajoonibiotech.com/pdf/nomination- and-remuneration-policy.pdf.

34. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS

Details of loans, guarantees and investments under the provisions of Section 186 of the Act read with the Companies (Meetings of Board and its Powers) Rules, 2014, as on 31st March, 2023, are set out in Notes to the financial statements of the Company.

35. BORROWINGS

Total borrowings of the company both long term and short term as on 31st March, 2023 are amounting Rs. 517.7 lacs as compared to previous year ended 31st March, 2022 of amounting Rs. 535 lacs (For details Refer Note No. 12 and 14 of the Audited Financial Statements).

36. WHISTLE BLOWER POLICY AND VIGIL MECHANISM

Section 177(9) of the Companies Act, 2013 and Regulation 22 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, inter alia, provides for a mandatory requirement for all listed companies to establish a mechanism called the Whistle Blower Policy for Directors and employees to report concerns of unethical behavior, actual or suspected, fraud or violation or the Companys code of conduct or ethics policy. In line with this requirement, the Company has framed a "Whistle Blower Policy", which is placed on the Companys website. The Whistle Blower Policy as approved by the Board is uploaded on the Companys website at

https://www.aioonibiotech.com/ and direct web link to the policy is at https://www.aioonibiotech.com/pdf/whistle blo wer policy.pdf.

37. FAMILIARIZATION POLICY

Pursuant to the provisions of Regulation 25(7) of Listing Regulations, 2015, the Board has framed a policy to familiarize Independent Directors about the Company. The direct web link to the policy is at https://www.aioonibiotech.com/pdf/familiarisatio n programme.pdf.

38. DISCLOSURES UNDER SEXUAL HARRASMENT OF WOMEN AT WORKPLACE (PREVENTION, PROHIBITION & REDRESSAL) ACT, 2013

The Company has in place a Prevention of Sexual Harassment Policy pursuant to the Sexual Harassment of Women at workplace (Prevention, Prohibition and Redressal) Act, 2013. An Internal Complaints Committee has also been set up to redress complaints received regarding sexual harassment. All employees (Permanent, contractual, temporary, trainees) are covered under this policy. No complaint has been received during the year under review.

39. LISTING FEES

The equity shares of the Company are listed on the National Stock Exchange. The listing fee for the year 2023-24 has already been paid.

40. TRADE RELATIONS

The Board wishes to place on record its appreciation for the support and co-operation that the Company received from its suppliers, distributors, retailers and other associates. The Company has always looked upon them as partners in its progress and has happily shared with them rewards of growth.

It will be Companys endeavor to build and nurture strong links based on mutuality, respect and cooperation with each other and consistent with customer interest.

41. INTERNAL AUDITORS & AUDITORS REPORT

As required under section 138 of the Companies Act, 2013 read with Rule 13 of the Companies (Accounts) Rules, 2014 made there under, the Company has appointed Internal Auditors to assess the risk management and to ensure that risk management processes are efficient, effective, secure and compliant. It is the basic check of internal control of the organization. An internal audit is an organizational move to check, ensure, monitor and analyze its own business operations in order to determine how well it conforms to a set of specific criteria.

42. ADEQUACY OF INTERNAL FINANCIAL CONTROLS

Your Companys internal financial control ensures that all assets of the Company are properly safeguarded and protected, proper prevention and detection of frauds and errors and all transactions are authorized, recorded and reported appropriately.

Your Company has an adequate system of internal financial controls commensurate with its size and scale of operations, procedures and policies, ensuring orderly and efficient conduct of its business, including adherence to the Companys policies, safeguarding of its assets, prevention and detection of frauds and errors, accuracy and completeness of accounting records, and timely preparation of reliable financial information.

43.MAINTENANCE OF COST RECORDS

The maintenance of cost records for the services rendered by the company is not required pursuant to Section 148(1) of the Companies Act, 2013 read with rule 3 of Companies (Cost Records and Audit) Rules, 2014.

44. DEMATERILISATION OF SHARES

The Company has connectivity with NSDL & CDSL for dematerialization of its equity shares. The ISIN No. INE820Y01021 has been allotted for the Company. Further the Company does not have any Equity shares lying in the Suspense Account.

45. HUMAN RESOURCE

The relationship with employees continues to be harmonious. The company always considers its human resource as its most valuable asset. Imparting adequate and specialized training to its employees is ongoing exercise in the company.

46. TRANSFER TO INVESTOR PROTECTION AND EDUCATION FUND (IEPF)

Since there was no unpaid/unclaimed Dividend declared or paid by the Company, the provisions of Section 125 of the Companies Act, 2013 do not apply.

47. COMPLIANCE WITH SECRETARIAL STANDARDS ON BOARD AND GENERAL MEETINGS

During the year under review, the Company has duly complied with the applicable provisions of the Secretarial Standards on Meetings of the Board of Directors (SS-1) and General Meetings (SS-2) issued by The Institute of Company Secretaries of India (ICSI).

48. SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS

There were no significant and material orders passed by the Regulators, Courts or Tribunals, during the year under review, which would impact the going concern status of the Company and its operations in future.

49. DISCLOSURE IN RESPECT OF VOTING RIGHTS NOT EXERCISED DIRECTLY BY THE EMPLOYEES IN RESPECT OF SHARES TO WHICH SCHEME FOR PROVISION OF MONEY FOR PURCHASE OF OR SUBSCRIPTION FOR SHARES BY EMPLOYEES OR BY TRUSTEES FOR THE BENEFIT OF EMPLOYEES

The disclosure under the provisions of Section 67(3) read with Rule 16(4) of the Companies (Share Capital and Debentures) Rules, 2014 in respect of voting rights not exercised directly by the employees in respect of shares to which scheme for provision of money for purchase of or subscription for shares by employees or by trustees for the benefit of employees is not applicable to the company.

50. PREVENTION OF INSIDER TRADING:

The Company has adopted a Code of Conduct to regulate, monitor and report trading by insiders under the SEBI

(Prohibition of Insider Trading) Regulations, 2015. This Code requires pre-clearance for dealing in the companys shares and prohibits the purchase or sale of Company shares by the Directors and the designated employees while in possession of unpublished price sensitive information in relation to the Company and during the period when the Trading Window is closed. The Board is responsible for implementation of the Code.

51. DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 (31 OF 2016) DURING THE YEAR ALONGWITH THEIR STATUS AS AT THE END OF THE FINANCIAL YEAR.

There are no proceedings initiated/ pending against your company under the Insolvency and Bankruptcy Code, 2016.

52. DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS ALONG WITH THE REASONS THEREOF.

During the period under review, there was no onetime settlement with any Bank or Financial Institution. Hence, no valuation was required to be undertaken.

53. ACKNOWLEDGEMENTS AND APPRECIATION

Your Directors would like to express their appreciation for assistance and co-operation received from the financial institutions, banks, Government authorities, customers, vendors and members during the year under review. Your Directors also wish to place on record their deep sense of appreciation for the committed services by the executives, staff and workers of the Company and the shareholders for their support and confidence reposed on the Company.